← ANALYST RATINGS · TIPRANKS
Mineralys Therapeutics, Inc. (MLYS): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy6 Buy1 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
$47.86+135.7% upside
Based on 7 price targets given in the last 3 months, the average target is $47.86, the highest $56.00, the lowest $29.00. The average is +135.7% from the last price of $20.30.
Highest target $56.00
Average target $47.86
Lowest target $29.00
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.50 → $21.00−10.6% | Hold | +3.4% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $22.50 → $20.50−8.9% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $23.50 → $21.00−10.6% | Hold | +3.4% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.00 → $20.50−10.9% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.50 → $20.50−12.8% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.50 → $21.00−10.6% | Hold | +3.4% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $24.50 → $23.50−4.1% | Hold | +15.8% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $24.00 → $22.50−6.2% | Hold | +10.8% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $25.00 → $23.50−6.0% | Hold | +15.8% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $24.00 → $23.00−4.2% | Hold | +13.3% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $25.00 → $23.50−6.0% | Hold | +15.8% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $24.50 → $23.50−4.1% | Hold | +15.8% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $49.00 | Buy | +141.4% | Reiterated | 12.10.26on TipRanks 09:10 | −4.8%next day −5.5% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $56.00 | Buy | +175.9% | Reiterated | 12.10.26on TipRanks 06:30 | −4.8%next day −5.5% | ↗ |
| Name not given | — | $29.00 | Hold | +42.9% | Initiated | 11.10.26on TipRanks Oct 12 05:45 | −4.8%next day −5.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.50 → $24.50+4.3% | Hold | +20.7% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.00 → $24.00+4.3% | Hold | +18.2% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $23.50 → $25.00+6.4% | Hold | +23.2% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.00 → $24.00+4.3% | Hold | +18.2% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.50 → $25.00+6.4% | Hold | +23.2% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.50 → $24.50+4.3% | Hold | +20.7% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.00 → $23.50+2.2% | Hold | +15.8% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $22.50 → $23.00+2.2% | Hold | +13.3% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $22.50 → $23.00+2.2% | Hold | +13.3% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.00 → $23.50+2.2% | Hold | +15.8% | Reiterated | 09.10.26on TipRanks 11:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $25.00 → $23.00−8.0% | Hold | +13.3% | Reiterated | 07.10.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $24.00 → $22.50−6.2% | Hold | +10.8% | Reiterated | 07.10.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $25.00 → $23.50−6.0% | Hold | +15.8% | Reiterated | 07.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $24.50 → $22.50−8.2% | Hold | +10.8% | Reiterated | 07.10.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $25.00 → $23.50−6.0% | Hold | +15.8% | Reiterated | 07.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $25.00 → $23.00−8.0% | Hold | +13.3% | Reiterated | 07.10.26on TipRanks 08:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $26.00 → $25.00−3.8% | Hold | +23.2% | Reiterated | 03.10.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $26.00 → $24.00−7.7% | Hold | +18.2% | Reiterated | 03.10.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 → $25.00−7.4% | Hold | +23.2% | Reiterated | 03.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $26.00 → $24.50−5.8% | Hold | +20.7% | Reiterated | 03.10.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $27.00 → $25.00−7.4% | Hold | +23.2% | Reiterated | 03.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $26.00 → $25.00−3.8% | Hold | +23.2% | Reiterated | 03.10.26on TipRanks 08:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $27.00 → $26.00−3.7% | Hold | +28.1% | Reiterated | 01.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 → $26.00−3.7% | Hold | +28.1% | Reiterated | 01.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 → $26.00−3.7% | Hold | +28.1% | Reiterated | 01.10.26on TipRanks 08:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $27.00 | Hold | +33.0% | Reiterated | 29.09.26on TipRanks 09:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $26.00 | Hold | +28.1% | Reiterated | 29.09.26on TipRanks 09:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 | Hold | +33.0% | Reiterated | 29.09.26on TipRanks 09:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 | Hold | +33.0% | Reiterated | 29.09.26on TipRanks 09:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $27.00 | Hold | +33.0% | Reiterated | 29.09.26on TipRanks 09:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 | Hold | +33.0% | Reiterated | 29.09.26on TipRanks 09:06 | — | |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $52.00 | Buy | +156.2% | Reiterated | 12.08.26on TipRanks Aug 13 07:10 | −1.3%next day −4.2% · 5 days +0.1% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $49.00 | Buy | +141.4% | Assigned | 12.08.26on TipRanks 09:30 | −1.3%next day −4.2% · 5 days +0.1% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $42.00 → $40.00−4.8% | Buy | +97.0% | Reiterated | 12.08.26on TipRanks 08:15 | −1.3%next day −4.2% · 5 days +0.1% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $55.00 | Buy | +170.9% | Reiterated | 12.08.26on TipRanks 07:10 | −1.3%next day −4.2% · 5 days +0.1% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $54.00 | Buy | +166.0% | Reiterated | 12.08.26on TipRanks 06:25 | −1.3%next day −4.2% · 5 days +0.1% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $56.00 | Buy | +175.9% | Reiterated | 12.08.26on TipRanks 06:15 | −1.3%next day −4.2% · 5 days +0.1% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $52.00 | Buy | +156.2% | Reiterated | 07.05.26on TipRanks 09:45 | −2.2%next day −0.2% · 5 days −9.4% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Buy | — | Reiterated | 06.05.26on TipRanks 19:35 | −2.2%next day −0.2% · 5 days −9.4% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 11.11.25on TipRanks Nov 12 04:40 | +5.6%next day +0.4% · 5 days −4.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Mineralys Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $51.00 at a price of $25.13 (+102.9%); now: $47.86 at $20.30 (+135.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 8 | 8 | 8 | 5 | 7 |
| Buy | 4 | 4 | 3 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.56 (from $-0.60 to $-0.45). Last quarter: $-2.85.
Best top-analyst consensus in the sector · Healthcare
About Mineralys Therapeutics, Inc.
- CEO: Jon Congleton
- Employees: 76
- 150 N. Radnor Chester Rd., Radnor, PA, 19087, US
- mineralystx.com
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Data from the stock’s TipRanks forecast page, read 91 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗